Management of elderly patients with delirium or dementia in Swiss nursing homes;Du delirium au syndrome démentiel: Prise en charge médicamenteuse dans les EMS fribourgeois

Revue Medicale Suisse

Volumn 3, Issue 132, 2007, Pages 2519-2530

  Locca, Jean François ^a   Zumbach, Serge ^b   Büla, Christophe ^c,d   Bugnon, Olivier ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b HPC   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d CUTR Sylvana   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; GALANTAMINE; HALOPERIDOL; MEMANTINE; OLANZAPINE; RISPERIDONE; RIVASTIGMINE;

CLINICAL FEATURE; CONFUSION; DELIRIUM; DEMENTIA; DIFFERENTIAL DIAGNOSIS; ELDERLY CARE; HEALTH PROGRAM; HUMAN; INTERDISCIPLINARY EDUCATION; MEDICAL LITERATURE; NURSING HOME; REVIEW;

AGED; ALGORITHMS; ANTIPSYCHOTIC AGENTS; CHOLINESTERASE INHIBITORS; DECISION TREES; DELIRIUM; DEMENTIA; HOMES FOR THE AGED; HUMANS; NOOTROPIC AGENTS; NURSING HOMES; SWITZERLAND;

EID: 36849091829     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Bugnon O, Buchmann M. Assistance pharmaceutique des homes médicalisés. Managed care 1998;3:13-7.
2. Locca JF, Michiellan E, Bugnon O. Medikamentenkosten dans Partnerschaft unter Kontrolle. Managed care 2006;3:10-3.
3. Matthews FE, Dening T. Prevalence of dementia in institutional care. Lancet 2002;360:225-6.
4. Lyketsos CG, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the cardiovascular health study. JAMA 2002;288:1475-83.
5. Lawlor PG, Fainsinger RL, Bruera ED. Delirium at the end of life: Critical issues in clinical practice and research. JAMA 2000;284:2427-9.
6. Schenk F, Leuba G, Büla C. Du vieillissement cérébral à la maladie d'Alzheimer: Autour de la notion de plasticité. Bruxelles: De Boeck, 2004.
7. ** Waldemar G, et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007;14:e1-26.
8. Agency for health research and quality (AHRQ). Evidence report/technology assessment no 97, pharmacological treatment of dementia. McMaster University evidence-based practice center 2004. Ref type: Electronic citation.
9. Birks J, Grimley EJ, Lakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2000;CD001191.
10. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2006;CD001190.
11. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;CD005593.
12. Craig D, Birks J. Rivastigmine for vascular cognitive impairment. Cochrane Database Syst Rev 2005;CD004744.
13. Craig D, Birks J. Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev 2006;CD004746.
14. * Lonergan E, Britton AM, Luxenberg J, Wyller T. Antipsychotics for delirium. Cochrane Database Syst Rev 2007;CD005594.
15. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev 2006;CD001747.
16. Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database Syst Rev 2006;CD004747.
17. Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev 2004;CD004395.
18. * McShane R, Areosa SA, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006;CD003154.
19. National institue for clinical excellence (NICE). Dementia: Supporting people with dementia and their carers in health and social care. London: NICE, 2006. Ref type: Electronic citation.
20. National institue for clinical excellence (NICE). Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease. National institue for health and clinical excellence 2006. Ref type: Electronic citation.
21. ** Scottish intercollegiate guidelines network (SIGN). Management of patients with dementia: A national clinical guideline. Edinburgh: SIGN, 2006. Ref type: Electronic citation.
22. * Wild R, Pettit T, Burns A. Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst Rev 2003;CD003672.
23. * Han CS, Kim YK. A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics 2004;45:297-301.
24. Inouye SK. Delirium in older persons. N Engl J Med 2006;354:1157-65.
25. Laurila JV, Pitkala KH, Strandberg TE, Tilvis RS. Delirium among patients with and without dementia: Does the diagnosis according to the DSM-IV differ from the previous classifications? Int J Geriatr Psychiatry 2004;19:271-7.
26. * Marcantonio ER. Clinical management and prevention of delirium. Psychiatry 2005;4:68-72.
27. Neef D, Walling AD. Dementia with Lewy bodies: An emerging disease. Am Fam Physician 2006;73:1223-9.
28. Turner S. Behavioural symptoms of dementia in residential settings : A selective review of non-pharmacological interventions. Aging Ment Health 2005;9:93-104.
29. Kim KY, Bader GM, Kotlyar V, Gropper D. Treatment of delirium in older adults with quetiapine. J Geriatr Psychiatry Neurol 2003;16:29-31.
30. * Mosimann UP, McKeith IG. Dementia with lewy bodies-diagnosis and treatment Swiss Med Wkly 2003;133:131-42.
31. Sasaki Y, et al. A prospective, open-label, flexible-dose study of quetiapine in the treatment of delirium. J Clin Psychiatry 2003;64:1316-21.
32. Ather SA, Shaw SH, Stoker MJ. A comparison of chlormethiazole and thioridazine in agitated confusional states of the elderly. Acta Psychiatr Scand 1986;(Suppl 329):81-91.
33. Holsinger T, Deveau J, Boustani M, Williams JW Jr. Does this patient have dementia? JAMA 2007;297:2391-404.
34. McKhann G, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of health and human services task force on Alzheimer's disease. Neurology 1984;34:939-44.
35. Chen P, Ganguli M, Mulsant BH, DeKosky ST. The temporal relationship between depressive symptoms and dementia: A community-based prospective study. Arch Gen Psychiatry 1999;56:261-6.
36. Roman GC, et al. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN international workshop. Neurology 1993;43:250-60.
37. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980;7:486-8.
38. McKeith IG, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 1996;47:1113-24.
39. Neary D, et al. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology 1998;51:1546-54.
40. McKhann GM, et al. Clinical and pathological diagnosis of frontotemporal dementia: Report of the work goup on frontotem poral dementia and pick's disease. Arch Neurol 2001;58:1803-9.